Multicenter Biologic Assignment Trial Comparing Reduced-Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care In Patients Aged 50 to 75 with Intermediate-2 and High-Risk Myelodysplastic Syndrome*. Biol Blood Marrow Transplant, 20, 1566-1572. presented at the 10/2014. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/24972249. (2014).
Phase 3 Clinical trial of Steroids/Mycophenolate Mofetil vs Steroids/Placebo as Therapy for Acute GVHD: BMT CTN 0802. Blood, 124, 3221-3227. presented at the 11/2014. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/25170121. (2014).
Tacrolimus/Sirolimus vs Tacrolimus/Methotrexate as GVHD Prophylaxis After Matched, Related Donor Allogeneic HCT. Blood, 124, 1372-1377. presented at the 08/2014. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/24982504. (2014).
Fludarabine-Based Conditioning for Marrow Transplantation From Unrelated Donors in Severe Aplastic Anemia: Early Results of a Cyclophosphamide Dose De-Escalation Study Show Life-Threatening Adverse Events at Predefined Cyclophosphamide Dose Levels. Biol Blood Marrow Transplant, 18, 1007-1011. presented at the 07/2012. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/22546497. (2012).
Tacrolimus/Sirolimus vs. Tacrolimus/Methotrexate for GVHD Prophylaxis After HLA-Matched, Related Donor Hematopoietic Stem Cell Transplantation: Results of BMT CTN Trial 0402. In 54th Annual ASH Meeting. presented at the 08/12/2012, Atlanta, GA. Retrieved from http://www.hematology.org/Meetings/Annual-Meeting/. (2012).